MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ
5.23
+0.32
+6.52%
Closed 19:04 05/24 EDT
OPEN
4.950
PREV CLOSE
4.910
HIGH
5.23
LOW
4.910
VOLUME
896.86K
TURNOVER
0
52 WEEK HIGH
7.00
52 WEEK LOW
3.295
MARKET CAP
304.38M
P/E (TTM)
-61.8203
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VNDA last week (0520-0524)?
Weekly Report · 1d ago
BUZZ-Vanda Pharmaceuticals down after rejecting Future Pak's revised takeover offer
Vanda Pharmaceuticals down after rejecting Future Pak's revised takeover offer of $ to $ per share. Company says board has rejected "unsolicited" takeover proposal. Shares of Vanda are down at $ in aftermarket trading. Future Pak did not immediately respond to a request for comment.
Reuters · 3d ago
Vanda Pharma Rejects Future Pak's Sweetened Takeover Bid
Dow Jones · 3d ago
UPDATE 2-Vanda Pharmaceuticals rejects Future Pak's revised takeover offer
Vanda Pharmaceuticals rejects Future Pak's revised takeover offer. The company said the revised offer substantially undervalued the company. Future Pak had in May sweetened its buyout offer for Vanda to include contingent value rights. Vanda in April rejected a takeover proposal from Future Pak.
Reuters · 3d ago
Vanda Pharmaceuticals rejects sweetened bid from Future Pak
Healthcare M&A Vanda Pharmaceuticals rejects sweetened bid from Future Pak. Vanda said the offer for $ to $ per share in cash "substantially undervalues" the company. Future Pak earlier this month made a sweetened takeover offer for Vanda.
Seeking Alpha · 3d ago
Vanda Pharmaceuticals rejects Future Pak's deal
Reuters · 3d ago
Vanda Pharmaceuticals Rejects Revised Unsolicited Acquisition Proposal From Future Pak, Concluding It Undervalues The Company; Board Unanimously Decides Proposal Is Not In The Best Interests Of Shareholders
Benzinga · 3d ago
*Vanda Pharmaceuticals: Future Pak's Offer to Buy Company for $7.25 to $7.75 a Share Plus Certain Contingent Value Rights Substantially Undervalues Company
Dow Jones · 3d ago
More
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.